Noninvasive image texture analysis differentiates K-ras mutation from pan-wildtype NSCLC and is prognostic
Non-invasive characterization of a tumor's molecular features could enhance treatment management. Quantitative computed tomography (CT) based texture analysis (QTA) has been used to derive tumor heterogeneity information, and the appearance of the tumors has been shown to relate to patient outc...
Saved in:
Published in: | PloS one Vol. 9; no. 7; p. e100244 |
---|---|
Main Authors: | , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Public Library of Science
02-07-2014
Public Library of Science (PLoS) |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Non-invasive characterization of a tumor's molecular features could enhance treatment management. Quantitative computed tomography (CT) based texture analysis (QTA) has been used to derive tumor heterogeneity information, and the appearance of the tumors has been shown to relate to patient outcome in non-small cell lung cancer (NSCLC) and other cancers. In this study, we examined the potential of tumoral QTA to differentiate K-ras mutant from pan-wildtype tumors and its prognostic potential using baseline pre-treatment non-contrast CT imaging in NSCLC.
Tumor DNA from patients with early-stage NSCLC was analyzed on the LungCarta Panel. Cases with a K-ras mutation or pan-wildtype for 26 oncogenes and tumor suppressor genes were selected for QTA. QTA was applied to regions of interest in the primary tumor. Non-parametric Mann Whitney test assessed the ability of the QTA, clinical and patient characteristics to differentiate between K-ras mutation from pan-wildtype. A recursive decision tree was developed to determine whether the differentiation of K-ras mutant from pan-wildtype tumors could be improved by sequential application of QTA parameters. Kaplan-Meier survival analysis assessed the ability of these markers to predict survival.
QTA was applied to 48 cases identified, 27 had a K-ras mutation and 21 cases were pan-wildtype. Positive skewness and lower kurtosis were significantly associated with the presence of a K-ras mutation. A five node decision tree had sensitivity, specificity, and accuracy values (95% CI) of 96.3% (78.1-100), 81.0% (50.5-97.4), and 89.6% (72.9-97.0); respectively. Kurtosis was a significant predictor of OS and DFS, with a lower kurtosis value linked with poorer survival.
Lower kurtosis and positive skewness are significantly associated with K-ras mutations. A QTA feature such as kurtosis is prognostic for OS and DFS. Non-invasive QTA can differentiate the presence of K-ras mutation from pan-wildtype NSCLC and is associated with patient survival. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Competing Interests: GJW is on the speaker's bureau for Genentech, Pfizer, Celgene, and Eli Lilly, and has received honoraria from Quintiles and Medscape. Sequenom, Inc. provided his lab the LungCarta Panel assay analysis, and had no role in the control of the data and information submitted for publication. RLK is an employee and stockholder in Imaging Endpoints, a core lab that supports clinical trials. BG and KM are shareholders in TexRAD Ltd, a company developing and marketing the tumor textural analysis software described in this manuscript, all other authors had control of the data and information submitted for publication. These disclosures do not alter the authors' adherence to PLOS ONE policies on sharing data and materials. There are no other author disclosures. Conceived and designed the experiments: GJW RLK. Performed the experiments: PYC RLK. Analyzed the data: GJW BG KAM RLK. Contributed reagents/materials/analysis tools: DHC PYC SF. Wrote the paper: GJW BG KAM RLK. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0100244 |